Inventor · disambiguated record
Mehdi Gasmi
Also filed as: GASMI MEHDI
7 granted patents·11 pending applications·51 citations·filing 2001–2022
82Inventor score
Top patents by PatentIndex Score
18 records- 0189US11510950B2Variant AAV capsids for intravitreal deliveryADVERUM BIOTECHNOLOGIES INC·Filed 2020·Granted Nov 29, 2022·4 cites·32 claims
- 0285US10584328B2Mutant viral capsid libraries and related systems and methodsADVERUM BIOTECHNOLOGIES INC·Filed 2016·Granted Mar 10, 2020·3 cites·20 claims
- 0376US8092429B2Needle assembly for use in delivering precise dosages of proteinaceous pharmaceutical compositions and methods for use of sameGASMI MEHDI·Filed 2010·Granted Jan 10, 2012·20 cites·9 claims
- 0474US8242093B2Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic proteinBARTUS RAYMOND T·Filed 2009·Granted Aug 14, 2012·4 cites·12 claims
- 0570US7837668B2Needle assembly for use in delivering precise dosages of proteinaceous pharmaceutical compositions and methods for use of sameCEREGENE INC·Filed 2006·Granted Nov 23, 2010·20 cites·6 claims
- 0669US2023322911A1Compositions and methods for reducing ocular neovascularizationADVERUM BIOTECHNOLOGIES INC·Filed 2022·Application pending·0 cites
- 0766US2022235371A1Scalable lentiviral vector production system compatible with industrial pharmaceutical applicationsGENETHON·Filed 2021·Application pending·0 cites
- 0864US11427931B2Mutant viral capsid libraries and related systems and methodsADVERUM BIOTECHNOLOGIES INC·Filed 2020·Granted Aug 30, 2022·0 cites·16 claims
- 0964US2022265740A1Treatment of amd using aav2 variant with afliberceptADVERUM BIOTECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 1060US2019100582A1Compositions and methods for reducing ocular neovascularizationADVERUM BIOTECHNOLOGIES INC·Filed 2018·Application pending·0 cites
- 1160US2019211360A1Scalable lentiviral vector production system compatible with industrial pharmaceutical applicationsGENETHON·Filed 2019·Application pending·0 cites
- 1260US2019151409A1Treatment of amd using aav2 variant with afliberceptADVERUM BIOTECHNOLOGIES INC·Filed 2018·Application pending·0 cites
- 1353US2014315294A1Scalable lentiviral vector production system compatible with industrial pharmaceutical applicationsGENETHON·Filed 2012·Application pending·0 cites
- 1447US2020297869A1Sequential intravitreal administration of aav gene therapy to contralateral eyesADVERUM BIOTECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 1545US8420619B2Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic proteinBARTUS RAYMOND T·Filed 2011·Granted Apr 16, 2013·0 cites·10 claims
- 1644US2021100856A1Methods of treating ocular neovascular diseases using aav2 variants encoding afliberceptADVERUM BIOTECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 1743US2019160187A1Gene therapy for the treatment of aldehyde dehydrogenase deficiencyUNIV CORNELL·Filed 2017·Application pending·0 cites
- 1843US2003003565A1Functional lentiviral vector from an MLV-based backboneFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mehdi Gasmi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →